Status:
COMPLETED
The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy
Lead Sponsor:
Duchesnay Inc.
Collaborating Sponsors:
Premier Research
Conditions:
Nausea and Vomiting of Pregnancy
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a plac...
Detailed Description
Nausea and vomiting of pregnancy (NVP), also known as "morning sickness," is a common condition that affects a large percentage of pregnant women. The symptoms can range from mild nausea to severe nau...
Eligibility Criteria
Inclusion
- The patient has signed a written informed consent to participate in the study and has agreed to follow dosing instructions and complete all required study visits.
- The patient is a pregnant female age equal to or greater than 18 years old.
- The patient's entry ultrasound indicates a viable pregnancy and confirms gestational age of the fetus is 7-14 weeks at the anticipated time of the first dose of study medication or placebo. If an ultrasound was done within 4 weeks of the admission visit, and results can be obtained, an additional ultrasound is not necessary.
- The patient is suffering from NVP and has a Pregnancy Unique Quantification of Emesis (PUQE) score ≥6.
- The patient has not responded to conservative management consisting of dietary/lifestyle advice according to the 2004 ACOG Practice Bulletin.
- The patient agrees, if on a multivitamin, to continue on their current dose of multivitamin for the duration of the trial.
- The patient does not plan termination of the pregnancy.
Exclusion
- The investigator confirms the patient's nausea and vomiting is of etiology other than Nausea and Vomiting of Pregnancy (NVP).
- The patient has gestational trophoblastic disease or multifetal gestation.
- The patient has a condition for which antihistamines, in the opinion of the investigator, are contraindicated (epilepsy, alcoholism, glaucoma, chronic lung disease, urinary retention, heart block, etc.).
- The patient has used antihistamines, anticholinergics, dopamine antagonists, serotonin antagonists, ginger, or anti-emetic therapy (including acupressure, acupuncture, homeopathic remedies, medical hypnosis, relief bands etc) to treat NVP in the previous 48 hours or plans to do so during the study .
- The patient is using drugs that have anticholinergic activity (e.g., tricyclic antidepressants).
- The patient is taking multivitamins containing more than 10 mg of vitamin B6, or plans to do so during the study.
- The patient is taking supplementary vitamin B6 in addition to any multivitamin preparation, or plans to do so during the study.
- The patient is currently drinking any amount of alcohol.
- The patient has any condition that might interfere with the conduct of the study.
- The patient is likely to be unable to comply with study procedures because of inadequate cognitive skills.
- The patient has received an investigational drug within 30 days before enrollment in this study or is scheduled to receive an investigational drug during the course of this study.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT00614445
Start Date
January 1 2008
End Date
December 1 2009
Last Update
November 23 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington Hospital Center Physicians
Washington D.C., District of Columbia, United States, 20010
2
Georgetown University Hospital
Washington D.C., District of Columbia, United States, 20057
3
National Naval Medical Center
Bethesda, Maryland, United States, 20889
4
Magee-Womens Hospital of University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213